Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/1097-0142(1967)20:5<865::aid-cncr2820200546>3.0.co;2-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Extracellular ATP Release Triggered by I-Trastuzumab Mitigates Radiation-Induced Reduction in Cell Viability through the P2Y Receptor in SKOV3 Cells.
Biol Pharm Bull
November 2024
Department of Quantum-Applied Biosciences, Takasaki Institute for Advanced Quantum Science, National Institute for Quantum Science and Technology.
Intracellular ATP is released outside cells by various stimuli and is involved in cytoprotection by activating purinergic receptors. However, it remains unclear whether targeted radionuclide therapy induces extracellular ATP release. Here, we prepared I-labeled trastuzumab (I-trastuzumab) and examined extracellular ATP release and its roles in I-trastuzumab's growth inhibitory effects.
View Article and Find Full Text PDFComparison of Tumor Non-specific and PD-L1 Specific Imaging by Near-Infrared Fluorescence/Cerenkov Luminescence Dual-Modality In-situ Imaging.
Mol Imaging
July 2024
Department of Radiology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Background: Labeled antibodies are excellent imaging agents in oncology to non-invasively visualize cancer-related antigens expression levels. However, tumor tracer uptake (TTU) of specific antibodies in-vivo may be inferior to non-specific IgG in some cases.
Objectives: To explore factors affecting labeled antibody visualization by PD-L1 specific and non-specific imaging of nude mouse tumors.
Radioimmunotherapy Targeting B7-H3 glioma models enhanced antitumor efficacy by Reconstructing the tumor microenvironment.
Int J Biol Sci
September 2023
Department of Clinical Pharmacology, The First Affiliated Hospital of Soochow University, Suzhou, SZ, China.
Radionuclide drug conjugates (RDCs) with antibodies serve as a novel approach for the treatment of malignant tumors including glioblastoma. However, RDCs require optimal antibodies to work efficiently. Hu4G4, a novel B7-H3-targeting humanized monoclonal IgG1 antibody, is highly specific for the human B7-H3 protein (a marker of tumor cells, including glioblastoma cells).
View Article and Find Full Text PDFI-Labeled Anti-HER2 Nanobody for Targeted Radionuclide Therapy of HER2-Positive Breast Cancer.
Int J Nanomedicine
April 2023
Department of Nuclear Medicine, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China.
Purpose: The unique structure of nanobodies is advantageous for the development of radiopharmaceuticals for nuclear medicine. Nanobodies targeted to human epidermal growth factor receptor 2 (HER2) can be used as tools for the imaging and therapy of HER2-overexpressing tumors. In this study, we aimed to describe the generation of a I-labeled anti-HER2 nanobody as a targeted radionuclide therapy (TRNT) agent for HER2-positive breast cancer.
View Article and Find Full Text PDFRadioiodination, purification, and evaluation of antihuman tumor-derived immunoglobulin G light chain monoclonal antibody in tumor-bearing nude mice.
J Labelled Comp Radiopharm
March 2023
Department of Nuclear Medicine, Peking University First Hospital, Beijing, China.
We report the synthesis and biological evaluation of I-labeled antihuman tumor-derived immunoglobulin G (IgG) light chain monoclonal antibody (4E9) ([ I]I-4E9) as a promising probe for tumor imaging. [ I]I-4E9 was synthesized in radiochemical yield of 89.9 ± 4.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!